Jun 11 2025
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Posted at Jun 11 2025
h in News by Cara Weaver

PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Jun. 11, 2025– Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39^th Annual Meeting of the Associated Professional Sleep Societies (APSS) “SLEEP” on Wednesday, June 11, 2025, at 10:00 AM PDT in Seattle.

Check out the full article here.

Print page

Jun 11 2025 Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

0 events, 29

0 events, 29

2 events, 30

2 events, 30

1 event, 1

1 event, 1

2 events, 2

2 events, 2

1 event, 3

1 event, 3

1 event, 4

1 event, 4

1 event, 5

1 event, 5

0 events, 6

0 events, 6

2 events, 7

2 events, 7

1 event, 8

1 event, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

1 event, 11

1 event, 11

1 event, 12

1 event, 12

0 events, 13

0 events, 13

2 events, 14

2 events, 14

1 event, 15

1 event, 15

2 events, 16

2 events, 16

1 event, 17

1 event, 17

1 event, 18

1 event, 18

1 event, 19

1 event, 19

0 events, 20

0 events, 20

2 events, 21

2 events, 21

1 event, 22

1 event, 22

2 events, 23

2 events, 23

2 events, 24

2 events, 24

1 event, 25

1 event, 25

1 event, 26

1 event, 26

0 events, 27

0 events, 27

2 events, 28

2 events, 28

1 event, 29

1 event, 29

Jun 11 2025
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025